GER-009-06-AVX Early Therapy in Multiple Sclerosis

Biogen230 enrolled

Overview

This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.

This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.

Study Type

OBSERVATIONAL

Enrollment

230

Conditions

Relapsing-Remitting Multiple Sclerosis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * CIS (according to indication) or early Relapsing Remitting Multiple Sclerosis Exclusion Criteria: * treatment with DMT during the last 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.